{"id":"W2995889981","doi":"10.1016/j.jtho.2019.12.109","title":"Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":438,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Merck Sharp and Dohme; EMD Serono; Genentech; National Institutes of Health; Eli Lilly and Company; Ono Pharmaceutical; National Cancer Institute; Servier; Daiichi-Sankyo; Puma Biotechnology; AbbVie; Aminex Therapeutics; Roche; Celgene; Novartis; Meso Scale Diagnostics; Sanofi; MedImmune; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; PharmaMar; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009996665,0.0002358559,0.001218851,0.0001999744,0.00004100835,0.00001304516,0.0002058694,0.00006152418,0.00006456341],"category_scores_gemma":[0.001351026,0.0000961398,0.00009351825,0.0003036593,0.0003534702,0.000143763,0.0001491277,0.0005562214,0.000003563391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002783923,"about_ca_system_score_gemma":0.0006267462,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008047243,"about_ca_topic_score_gemma":0.0005026085,"domain_scores_codex":[0.9973777,0.0004771674,0.0009159373,0.0002610591,0.000661843,0.0003062979],"domain_scores_gemma":[0.9961249,0.001755912,0.0008028324,0.0003312647,0.0008797534,0.0001053543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5161662,0.001325251,0.2688271,0.0004311561,0.002822053,0.0005481734,0.01552558,0.00004368871,0.00008932441,0.00000121594,0.00259225,0.1916281],"study_design_scores_gemma":[0.03753588,0.04060886,0.9068954,0.003164282,0.0008380639,0.000166499,0.004564982,0.00005816817,0.0002884336,0.000127878,0.005507253,0.0002443253],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979326,0.01317492,0.000003813431,0.005980822,0.0003417527,0.0010635,0.00005762321,0.000005434149,0.0000461781],"genre_scores_gemma":[0.9892213,0.008209273,0.001575416,0.000432778,0.0002151885,0.00002653432,0.000004715879,0.00002429955,0.0002905317],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6380683,"threshold_uncertainty_score":0.3920467,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05916321030402624,"score_gpt":0.4761060156971092,"score_spread":0.416942805393083,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}